Generic Firms Fear FDA Pill Size Guidance Helps Brands Stifle Competition
This article was originally published in The Tan Sheet
Executive Summary
FDA final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.